PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Hoxha, Elion ^a   Harendza, Sigrid ^a   Pinnschmidt, Hans ^a   Panzer, Ulf ^a   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; CALCINEURIN INHIBITOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPASE A2 RECEPTOR; RENIN INHIBITOR; RITUXIMAB; STEROID; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; PROTEIN FUNCTION; PROTEINURIA; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; THROMBOEMBOLISM; AGED; DRUG EFFECTS; FOLLOW UP; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TREATMENT OUTCOME;

EID: 84908008812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110681     Document Type: Article

References (13)

1. Cattran D (2005) Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 16: 1188-1194.
2. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, et al. (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704.
3. Hladunewich MA, Troyanov S, Calafati J, Cattran DC (2009) The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4: 1417-1422.
4. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, et al. (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21.
5. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, et al. (2014) Phospholipase A2 Receptor autoantibody levels and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25: 1357-1366.
6. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, et al. (2013) Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421: 213-218.
7. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, et al. (1998) A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450.
8. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, et al. (1995) A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47: 1130-1135.
9. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, et al. (2012) Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416-1425.
10. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, et al. (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381: 744-751.
11. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, et al. (1993) Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89.
12. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, et al. (2012). Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 82: 797-804.
13. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, et al. (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550.